Robert G Micheletti

List of Publications by Year
in descending order

118 papers	3,003 citations	186265 28 h-index	189892 50 g-index
122 all docs	122 docs citations	122 times ranked	2994 citing authors

#	Article	IF	Citations
1	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101.	1.2	77
2	Targeted Therapeutics: Biologics, Small Molecules. , 2022, , 182-190.		0
3	Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatology, 2022, 158, 176.	4.1	31
4	Telemedicine and dermatology hospital consultations during the COVIDâ€19 pandemic: a multiâ€centre observational study on resource utilization and conversion to inâ€person consultations during the COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
5	Neutrophilic Dermatoses: a Clinical Update. Current Dermatology Reports, 2022, 11, 89-102.	2.1	14
6	Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. Journal of the American Academy of Dermatology, 2021, 84, 784-786.	1.2	5
7	Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease. Journal of the American Academy of Dermatology, 2021, 84, 1547-1553.	1.2	27
8	Low utility of radiologic imaging in evaluating cutaneous small-vessel vasculitis: A multi-institutional retrospective study. Journal of the American Academy of Dermatology, 2021, 84, 1197-1199.	1.2	3
9	Pregnancy in Hidradenitis Suppurativaâ€”Patient Perspectives and Practice Gaps. JAMA Dermatology, 2021, 157, 227.	4.1	6
10	Reply. Arthritis and Rheumatology, 2021, 73, 1089-1089.	5.6	0
11	Advances in cutaneous vasculitis research and clinical care. Annals of Translational Medicine, 2021, 9, 439-439.	1.7	1
12	Cutaneous Manifestations of COVID-19: Characteristics, Pathogenesis, and the Role of Dermatology in the Pandemic. , 2021, 107, 209-215.		3
13	Authors' reply to the comment â€œHigh-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativaâ€. Journal of the American Academy of Dermatology, 2021, 84, e203-e204.	1.2	0
14	Supportive care in the acute phase of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.5	22
15	Dermatologic support for oncology: Quantifying the consultative services received by hospitalized oncology patients. Journal of the American Academy of Dermatology, 2021, 85, 1367-1368.	1.2	1
16	Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatology, 2021, 157, 712.	4.1	19
17	Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal of Women's Dermatology, 2021, 7, 545-551.	2.0	2
18	Medical management of Stevens-Johnson syndrome/toxic epidermal necrolysis among North American dermatologists. Journal of the American Academy of Dermatology, 2021, , .	1.2	4

#	Article	IF	Citations
19	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-Î± Inhibitors?. American Journal of Clinical Dermatology, 2021, 22, 139-147.	6.7	6
20	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.5	25
21	Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. Journal of the American Academy of Dermatology, 2020, 82, 507-510.	1.2	15
22	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology, 2020, 82, 366-376.	1.2	165
23	A survey-based study of diagnostic and treatment concordance in standardized cases of cellulitis and pseudocellulitis via teledermatology. Journal of the American Academy of Dermatology, 2020, 82, 1221-1223.	1.2	18
24	Ablative fractional laser resurfacing for treatment of sclerosis and contractures in chronic graft-versus-host disease: A pilot study. Journal of the American Academy of Dermatology, 2020, 82, 984-986.	1.2	4
25	High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2020, 82, 1094-1101.	1.2	51
26	Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy. JAMA Dermatology, 2020, 156, 353.	4.1	14
27	Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions. Journal of the American Academy of Dermatology, 2020, 82, 1239-1241.	1.2	3
28	Improving Outcomes for Patients With Epidermal Necrolysis. JAMA Dermatology, 2020, 156, 1289.	4.1	0
29	Management of cutaneous vasculitis. Presse Medicale, 2020, 49, 104033.	1.9	20
30	Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. JAMA Dermatology, 2020, 156, 814.	4.1	5
31	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials, 2020, 21, 362.	1.6	14
32	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2020, 72, 1741-1747.	5.6	31
33	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology, 2020, 82, 1553-1567.	1.2	35
34	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
35	Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clinics in Dermatology, 2020, 38, 607-612.	1.6	22
36	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. Journal of the American Academy of Dermatology, 2020, 83, 1150-1159.	1.2	27

#	Article	IF	Citations
37	Retrospective review of drugâ€induced Stevensâ€Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatric Dermatology, 2020, 37, 461-466.	0.9	18
38	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatology, 2020, 156, 270.	4.1	49
39	How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. JAMA Dermatology, 2020, 156, 733.	4.1	22
40	Cutaneous Manifestations of Sexually Transmitted Infections. , 2020, , 133-151.		0
41	Nutritional dermatoses in the hospitalized patient. Cutis, 2020, 105, 296;302-308;E1;E2;E3;E4;E5.	0.3	0
42	The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€"Reply. JAMA Dermatology, 2019, 155, 1088.	4.1	8
43	Skin and Soft Tissue Infection in Transplant Recipients. , 2019, , 365-395.		0
44	Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12. British Journal of Dermatology, 2019, 181, 886-887.	1.5	0
45	Numerous Pink-Purple Papules in a Middle-aged Man. JAMA Dermatology, 2019, 155, 1308.	4.1	0
46	North American clinical management guidelines for hidradenitis suppurativa: AÂpublication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101.	1.2	206
47	Bullous dermatosis suspected in an 8-month-old child in Guinea-Bissau. Oxford Medical Case Reports, 2019, 2019, omz004.	0.4	3
48	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 76-90.	1.2	218
49	The potential costâ€savings of tumour necrosis factor inhibitors for hidradenitis suppurativa. British Journal of Dermatology, 2019, 180, 988-989.	1.5	2
50	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€"ABCD-10. JAMA Dermatology, 2019, 155, 448.	4.1	69
51	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	1.9	16
52	Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. Journal of the American Academy of Dermatology, 2019, 81, 1410-1412.	1.2	0
53	Reply to: â€œNew validated diagnostic criteria for pyoderma gangrenosumâ€. Journal of the American Academy of Dermatology, 2019, 80, e89.	1.2	0
54	Erythematous plaques and nodules on the abdomen and groin. Cutis, 2019, 104, E24-E26.	0.3	0

#	Article	IF	Citations
55	Neutrophilic dermatoses. Journal of the American Academy of Dermatology, 2018, 79, 1009-1022.	1.2	73
56	Neutrophilic dermatoses. Journal of the American Academy of Dermatology, 2018, 79, 987-1006.	1.2	122
57	Tobacco smoking and hidradenitis suppurativa: associated disease and an important modifiable risk factor. British Journal of Dermatology, 2018, 178, 587-588.	1.5	13
58	Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations. Clinics in Dermatology, 2018, 36, 561-566.	1.6	20
59	The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatology, 2018, 154, 409.	4.1	105
60	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
61	Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic EpidermalÂNecrolysis May Exclude PatientsÂwith Poor Prognostic Factors. Journal of Investigative Dermatology, 2018, 138, 2068-2072.	0.7	7
62	Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. Journal of the American Academy of Dermatology, 2018, 78, 303-309.e4.	1.2	76
63	The immune reconstitution of the skin following sexâ€mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry. British Journal of Dermatology, 2018, 178, e55-e56.	1.5	1
64	Introducing â€œImages in Dermatologyâ€• JAMA Dermatology, 2018, 154, 1255.	4.1	3
65	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the UnitedÂStates. Journal of Investigative Dermatology, 2018, 138, 2315-2321.	0.7	94
66	Enlarging red papulonodule on the chest. Cutis, 2018, 101, 78;117;118.	0.3	0
67	Update on calciphylaxis etiopathogenesis, diagnosis, and management. Cutis, 2018, 102, 395-400.	0.3	2
68	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 191-198.	1.2	52
69	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 201-207.	1.2	115
70	216 A new mortality prediction tool for Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of Investigative Dermatology, 2017, 137, S37.	0.7	1
71	Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy. American Journal of Dermatopathology, 2017, 39, e1-e2.	0.6	12
72	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. JAMA Dermatology, 2017, 153, 587.	4.1	30

#	Article	IF	Citations
73	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 1-9.	1.2	126
74	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 11-16.	1.2	68
75	A cross-sectional survey of voriconazole prescribers: Assessing current practice and knowledge of cutaneous side effects. Journal of the American Academy of Dermatology, 2017, 77, 769-770.	1.2	2
76	Joseph Goldbergerâ€"Public Health Champion and Investigator of Pellagra. JAMA Dermatology, 2017, 153, 1262.	4.1	2
77	Robert Chesebrough and the Dermatologic Wonder of Petroleum Jelly. JAMA Dermatology, 2017, 153, 1157.	4.1	3
78	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 197-218.	1.2	19
79	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 221-230.	1.2	17
80	Atypical retiform hemangioendothelioma arising in a patient with Milroy disease: a case report and review of the literature. Journal of Cutaneous Pathology, 2017, 44, 98-103.	1.3	2
81	Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host. BMJ Case Reports, 2017, 2017, bcr-2017-221053.	0.5	9
82	Alopecia neoplastica. BMJ Case Reports, 2017, 2017, bcr-2017-220215.	0.5	5
83	Atypical Manifestations of Graft-Versus-Host Disease. , 2017, , 149-160.		1
84	Developing academic work and evidence to guide the practice of inpatient dermatology. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 35-37.	1.6	1
85	Medical management of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 62-66.	1.6	3
86	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.	0.2	1
87	Refractory Cutaneous Alternariosis Successfully Treated With Mohs Surgery and Full-Thickness Skin Grafting. Dermatologic Surgery, 2016, 42, 426-429.	0.8	2
88	Cryptococcal cellulitis in a heart transplant recipient. JAAD Case Reports, 2016, 2, 403-405.	0.8	1
89	Diffuse HIV-associated seborrheic dermatitis â€“ a case series. International Journal of STD and AIDS, 2016, 27, 1342-1345.	1.1	31
90	FLT3Inhibitorâ€“Associated Neutrophilic Dermatoses. JAMA Dermatology, 2016, 152, 480.	4.1	25

#	Article	IF	Citations
91	Optimizing â€œbest availableâ€•medical options when practicing complex medical dermatology in resource-limited settings. Journal of the American Academy of Dermatology, 2016, 75, e171-e172.	1.2	0
92	Chronic idiopathic Sweet syndrome: A report of 2 cases. JAAD Case Reports, 2016, 2, 227-229.	0.8	5
93	Inpatient dermatology consultation in patients with hematologic malignancies. Journal of the American Academy of Dermatology, 2016, 75, 835-836.	1.2	17
94	A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials, 2016, 46, 48-51.	1.8	31
95	Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod. JAMA Neurology, 2016, 73, 355.	9.0	38
96	Small Vessel Vasculitis of the Skin. , 2016, , 233-244.		2
97	Purple curvilinear papules on the back. Cutis, 2016, 98, E5-E7.	0.3	0
98	Disseminated coccidioidomycosis masquerading as a ruptured epidermal inclusion cyst in a healthy young adult from Philadelphia. International Journal of Dermatology, 2015, 54, e441-e442.	1.0	0
99	The importance of multidisciplinary healthcare for paraneoplastic pemphigus. Special Care in Dentistry, 2015, 35, 143-147.	0.8	2
100	Cryptococcal meningitis presenting with headache and a pustular eruption in a heart transplant patient. Transplant Infectious Disease, 2015, 17, 716-718.	1.7	5
101	A Crusted Rash in a Patient With AIDS. JAMA - Journal of the American Medical Association, 2015, 313, 298.	7.4	6
102	Atypical manifestations of graft-versus-host disease. Journal of the American Academy of Dermatology, 2015, 72, 690-695.	1.2	30
103	Small Vessel Vasculitis of the Skin. Rheumatic Disease Clinics of North America, 2015, 41, 21-32.	1.9	58
104	An update on the diagnosis and treatment of hidradenitis suppurativa. Cutis, 2015, 96, 7-12.	0.3	8
105	Striking Follicular Eruption to Pegylated Liposomal Doxorubicin. American Journal of Dermatopathology, 2014, 36, 590-591.	0.6	7
106	Robotic teledermatopathology from an African dermatology clinic. Journal of the American Academy of Dermatology, 2014, 70, 952-954.	1.2	8
107	Hidradenitis Suppurativa: Current Views on Epidemiology, Pathogenesis, and Pathophysiology. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S48-S50.	1.6	32
108	Natural History, Presentation, and Diagnosis of Hidradenitis Suppurativa. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S51-S53.	1.6	28

#	Article	IF	Citations
109	What You Should Know About Hidradenitis Suppurativa: Information for Patients. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S60-S61.	1.6	0
110	Introduction. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S47-S47.	1.6	4
111	A Violaceous Plaque in an Immunosuppressed Patient. JAMA - Journal of the American Medical Association, 2012, 307, 2635.	7.4	5
112	Distal Matrix Glomus Tumor Presenting as Longitudinal Erythronychia: A Pearl for Surgical Management. Dermatologic Surgery, 2012, 38, 133-134.	0.8	2
113	An Enlarging Ulcer. American Journal of Medicine, 2011, 124, 915-917.	1.5	0
114	An approach to the hospitalized patient with urticaria and fever. Dermatologic Therapy, 2011, 24, 187-195.	1.7	2
115	Coronary atherosclerotic lesions in human immunodeficiency virusâ€“infected patients: a histopathologic study. Cardiovascular Pathology, 2009, 18, 28-36.	1.6	35
116	Calcification of the internal elastic lamina of coronary arteries. Modern Pathology, 2008, 21, 1019-1028.	5.5	34
117	Atherosclerotic oxalosis in coronary arteries. Cardiovascular Pathology, 2008, 17, 117-123.	1.6	42
118	MÃ¶nckeberg Sclerosis Revisited: A Clarification of the Histologic Definition of MÃ¶nckeberg Sclerosis. Archives of Pathology and Laboratory Medicine, 2008, 132, 43-47.	2.5	90